2型糖尿病治疗药物对心血管、肾脏及体重的影响:一项动态临床实践指南
该动态临床实践指南由国际专家组遵循GRADE方法制定,基于截至2024年7月31日的动态系统综述与网络Meta分析,针对2型糖尿病成人患者,按心血管和肾脏并发症风险分层,对SGLT-2抑制剂、GLP-1受体激动剂、非奈利酮和替尔泊肽四种药物给出推荐。
要点
- 低风险(≤3个心血管危险因素且无确立CVD或CKD):弱推荐反对使用SGLT-2抑制剂或GLP-1受体激动剂。
- 中风险(>3个心血管危险因素且无确立CVD或CKD;或确立CVD和/或CKD但并发症风险较低):弱推荐支持SGLT-2抑制剂或GLP-1受体激动剂;CKD成人弱推荐反对非奈利酮。
- 高风险(确立CVD和/或CKD且并发症风险较高,或确立心衰):强推荐支持SGLT-2抑制剂或GLP-1受体激动剂;CKD成人弱推荐支持非奈利酮。
核心结论
- 该动态临床实践指南按心血管和肾脏并发症风险分层,对2型糖尿病成人患者的四种优先药物给出推荐。
研究设计与样本
- 国际专家组(含两名患者伙伴、临床医生和方法学家)遵循可信指南标准,采用GRADE方法制定推荐。
- 推荐基于截至2024年7月31日更新的动态系统综述与网络Meta分析,以及关于风险预测模型和患者价值观与偏好的系统综述。
主要发现
- 低风险(三个或以下心血管危险因素且无确立心血管疾病或慢性肾脏病):弱推荐反对使用SGLT-2抑制剂或GLP-1受体激动剂。
- 中风险(超过三个心血管危险因素且无确立心血管疾病或慢性肾脏病;或确立心血管疾病和/或慢性肾脏病但并发症风险较低):弱推荐支持SGLT-2抑制剂或GLP-1受体激动剂;慢性肾脏病成人弱推荐反对非奈利酮。
- 高风险(确立心血管疾病和/或慢性肾脏病且并发症风险较高,或确立心力衰竭):强推荐支持SGLT-2抑制剂或GLP-1受体激动剂;慢性肾脏病成人弱推荐支持非奈利酮。
- 各风险层:肥胖成人弱推荐支持替尔泊肽。
关键数值与推荐
- 低风险:三个或以下心血管危险因素且无确立心血管疾病或慢性肾脏病。
- 中风险:超过三个心血管危险因素且无确立心血管疾病或慢性肾脏病;或确立心血管疾病和/或慢性肾脏病但并发症风险较低。
- 高风险:确立心血管疾病和/或慢性肾脏病且并发症风险较高,或确立心力衰竭。
- 推荐强度:低风险弱推荐反对SGLT-2抑制剂或GLP-1受体激动剂;中风险弱推荐支持SGLT-2抑制剂或GLP-1受体激动剂、弱推荐反对非奈利酮;高风险强推荐支持SGLT-2抑制剂或GLP-1受体激动剂、弱推荐支持非奈利酮;各风险层肥胖成人弱推荐支持替尔泊肽。
临床怎么用
- 该指南为2型糖尿病成人患者提供按心血管和肾脏并发症风险分层的药物推荐,以指导糖尿病管理。
- 指南指出部分药物可及性缺乏或成本高昂可能阻碍推荐在不同卫生保健系统中的实施。
局限性
- 指南指出部分药物可及性缺乏或成本高昂可能阻碍推荐在不同卫生保健系统中的实施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CLINICAL QUESTION: What are the benefits and harms of medications for adults with type 2 diabetes at varied risks of cardiovascular and kidney related complications? CONTEXT: Emerging clinical trials of novel medications have demonstrated benefits on cardiovascular, kidney, and weight related outcomes in people with type 2 diabetes. Dynamically updated practice guidelines adhering to standards of trustworthiness are necessary in response to a rapidly evolving evidence base and the availability of multiple medication alternatives. This living practice guideline incorporates the latest available medications and evidence and provides recommendations stratified by risks of cardiovascular and kidney complications to inform diabetes management. RECOMMENDATIONS: The panel issued risk-stratified recommendations regarding four prioritised medications for adults with type 2 diabetes (SGLT-2 inhibitors, GLP-1 receptor agonists, finerenone and tirzepatide):• Lower risk (three or fewer cardiovascular risk factors without established cardiovascular disease (CVD) or chronic kidney disease (CKD)): weak recommendation against SGLT-2 inhibitors or GLP-1 receptor agonists.• Moderate risk (more than three cardiovascular risk factors without established CVD or CKD; or established CVD and/or CKD at lower risk of complications): weak recommendation in favour of SGLT-2 inhibitors or GLP-1 receptor agonists; and a weak recommendation against finerenone in adults with CKD.• Higher risk (established CVD and/or CKD at higher risk of complications, or established heart failure): strong recommendation in favour of SGLT-2 inhibitors or GLP-1 receptor agonists; and a weak recommendation in favour of finerenone in adults with CKD.• Across risk strata: weak recommendation in favour of tirzepatide in adults with obesity. ABOUT THIS GUIDELINE AND HOW IT WAS CREATED: An international panel including two patient partners, clinicians, and methodologists produced these recommendations. The panel followed standards for trustworthy guidelines and used the GRADE approach, explicitly considering the balance of benefits, harms and burdens of treatment from an individual patient perspective. Recommendations were informed by a linked living systematic review and network meta-analysis evaluating relative benefits and harms updated to 31 July 2024; and by linked systematic reviews addressing risk prediction models and values and preferences of adults with type 2 diabetes. Candidate therapeutics are prioritised based on availability of sufficient randomised trial data, relevance to a global audience and likelihood of changing practice.This is the first version of the living guideline. The guideline is part of the BMJ Rapid Recommendations series. MAGICapp displays the most recent version of the guideline and full content including evidence summaries and decision aids; major updates will be published in The BMJ. We encourage re-use, adaptation and translation of these living guidelines, and recognise that the lack of availability or high costs of some medications may be prohibitive and will impact on how these recommendations are implemented across different health care systems.
引用
- Agarwal A, Mustafa R, Manja V, et al. Cardiovascular, kidney related, and weight loss effects of therapeutics for type 2 diabetes: a living clinical practice guideline. BMJ. 2025. PMID: 40813129. doi:10.1136/bmj-2024-082071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。